| | | | |
CUSIP No. 81728A108 | | Schedule 13G | | Page 5 of 9 |
ITEM 1. | (a) Name of Issuer: |
Sensei Biotherapeutics, Inc. (the “Issuer”).
| (b) | Address of Issuer’s Principal Executive Offices: |
1405 Research Blvd, Suite 125
Rockville, MD 20850
ITEM 2. | (a) Name of Person Filing: |
Each of the following is hereinafter individually referred to as a “Reporting Person” and collectively as the “Reporting Persons.” This statement is filed on behalf of:
Presight Sensei Co-Invest Fund, L.P. (“Presight Co-Invest”);
Presight Sensei Co-Invest Management, L.L.C. (“Presight Co-Invest Management”);
Apeiron Investment Group, Ltd. (“Apeiron”); and
Christian Angermayer.
| (b) | Address or Principal Business Office: |
The business address for (i) Presight Co-Invest and Presight Co-Invest Management is 340 South Lemon Avenue #3391 Walnut, CA 91789 and (ii) Apeiron and Christian Angermayer is Block A, Apt.12, Il-Piazzetta, Tower Road, SLM1605, Sliema, Malta.
| (c) | Citizenship of each Reporting Person is: |
Presight Co-Invest and Presight Co-Invest Management are organized under the laws of the state of Delaware. Apeiron is organized under the laws of the Malta. Mr. Angermayer is a German citizen.
| (d) | Title of Class of Securities: |
Common Stock, $0.0001 par value per share (“Common Stock”).
81728A108
Not applicable.